ENSC SEC Filings - Ensysce Biosciences, Inc.- Annual Report, Proxy Statement, Prospectus

Basic Stats

CIK

1716947

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ensysce Biosciences, Inc.

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

August 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 (August 13, 2025) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 (August 13, 2025) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorp
August 13, 2025	EX-99.1	Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval Receives $5.3 Million Ins Exhibit 99.1 Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval Receives $5.3 Million Installment from NIDA To Support Overdose Protection Program Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2 SAN DIEGO, CA /
August 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38306 ENSYSCE BIOSCIENCES,
June 5, 2025	EX-16.1	Letter dated June 5, 2025, from Moss Adams LLP. Exhibit 16.1 June 5, 2025 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Ensysce Biosciences, Inc. included under Item 4.01 of its Current Report on Form 8-K dated June 3, 2025 to be filed with the Securities and Exchange Commission. We agree with the statements concerning our Firm contained therein. Sincerely
June 5, 2025	8-K	Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2025 (June 3, 2025) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorporatio
May 13, 2025	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 (May 13, 2025) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorporatio
May 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38306 ENSYSCE BIOSCIENCES,
May 13, 2025	EX-99.1	Ensysce Biosciences Reports First Quarter 2025 Financial Results Receives U.S. Patent for Groundbreaking Treatment for Opioid Use Disorder Clinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection Exhibit 99.1 Ensysce Biosciences Reports First Quarter 2025 Financial Results Receives U.S. Patent for Groundbreaking Treatment for Opioid Use Disorder Clinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection SAN DIEGO, CA / May 13, 2025 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company developing innovative solu
May 9, 2025	CORRESP	Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 May 9, 2025 Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 May 9, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Lauren Sprague Hamill, Esq. Re: Ensysce Biosciences, Inc. Registration Statement on Form S-3 SEC File No. 333-286943 Filed May 2, 2025 Ladies and G
May 2, 2025	S-3	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	EX-FILING FEES	Filing fee table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ensysce Biosciences, Inc.
May 2, 2025	S-8	As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No.
May 2, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ensysce Biosciences, Inc.
April 24, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 (April 24, 2025) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorpor
April 24, 2025	EX-10.1	Form of Inducement Letter Agreement Exhibit 10.1 ENSYSCE BIOSCIENCES, INC. April 23, 2025 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Ensysce Biosciences, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.0001 per sh
April 24, 2025	EX-4.2	Form of placement agent warrant issued April 24, 2025 (incorporated by reference to Exhibit 4.2 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on April 24, 2025). Exhibit 4.2 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC
April 24, 2025	EX-99.1	Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds Exhibit 99.1 Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds SAN DIEGO, CA / ACCESSWIRE / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) (the “Company”), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the entry into definiti
April 24, 2025	EX-4.1	Form of Common Warrant Exhibit 4.1 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC
April 23, 2025	CORRESP	Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 April 23, 2025 Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 April 23, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Tyler Howes, Esq. Re: Ensysce Biosciences, Inc. Registration Statement on Form S-3 SEC File No. 333-286580 Filed April 16, 2025 Ladies and Gentl
April 22, 2025	CORRESP	Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 April 22, 2025 Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 April 22, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Tyler Howes, Esq. Re: Ensysce Biosciences, Inc. Registration Statement on Form S-3 SEC File No. 333-286580 Filed April 16, 2025 Ladies and Gentl
April 22, 2025	CORRESP	Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 April 22, 2025 Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 April 22, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Tyler Howes, Esq. Re: Ensysce Biosciences, Inc. Registration Statement on Form S-3 SEC File No. 333-286584 Filed April 16, 2025 Ladies and Gentl
April 16, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ensysce Biosciences, Inc.
April 16, 2025	S-3	As filed with the Securities and Exchange Commission on April 16, 2025 As filed with the Securities and Exchange Commission on April 16, 2025 Registration No.
April 16, 2025	S-3	As filed with the Securities and Exchange Commission on April 16, 2025 As filed with the Securities and Exchange Commission on April 16, 2025 Registration No.
April 16, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ensysce Biosciences, Inc.
April 1, 2025	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 (April 1, 2025) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorporat
March 31, 2025	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 (March 30, 2025) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorpor
March 31, 2025	EX-99.1	Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Exhibit 99.1 Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose,
March 31, 2025	424B5	ENSYSCE BIOSCIENCES, INC. 239,594 Shares of Common Stock 75,594 Pre-funded Warrants to Purchase up to 75,594 Shares of Common Stock Up to 75,594 Shares of Common Stock Underlying the Pre-Funded Warrants Filed Pursuant to Rule 424(b)(5) Registration No. 333-269157 PROSPECTUS SUPPLEMENT (To the Prospectus dated January 6, 2023) ENSYSCE BIOSCIENCES, INC. 239,594 Shares of Common Stock 75,594 Pre-funded Warrants to Purchase up to 75,594 Shares of Common Stock Up to 75,594 Shares of Common Stock Underlying the Pre-Funded Warrants Pursuant to this prospectus supplement and the accompanying prospectus,
March 31, 2025	EX-4.1	Form of Pre-funded Warrant Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: [] Initial Exercise Date: , 2025 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date
March 31, 2025	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 30, 2025, between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio
March 31, 2025	EX-4.3	Form of placement agent warrant issued March 31, 2025 (incorporated by reference to Exhibit 4.3 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on March 31, 2025). Exhibit 4.3 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC
March 31, 2025	EX-4.2	Form of Series A-5/A-6 common stock purchase warrant issued March 31, 2025 (incorporated by reference to Exhibit 4.2 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on March 31, 2025) Exhibit 4.2 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC
March 10, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38306 ENSYSCE BIOSCIENCES, INC.
March 10, 2025	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 (March 10, 2025) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorpor
March 10, 2025	EX-99.1	Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results Exhibit 99.1 Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR Groundbreaking Trial on PF614-MPAR Generates Positive Interim Results SAN DIEGO, CA / March 10, 2025 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical compa
February 14, 2025	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex-99-02142025110227.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of February 14, 2025, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United State
February 4, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2025 (January 12, 2025) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of inco
February 4, 2025	EX-10.1	Product Development and Commercial Manufacturing Supply Master Services Agreement Exhibit 10.1 PRODUCT Development AND COMMERCIAL MANUFACTURING SUPPLY MASTER SERVICES AGREEMENT This Product Development and Commercial Manufacturing Supply Master Services Agreement (this “Agreement”) is made as of January 12, 2025 (the “Effective Date”), by and between Galephar Pharmaceutical Research, Inc., a Puerto Rico corporation located at Carr. 925 M 6.1 Bo, Junquito, Humacao, PR 00791(“Gal
December 3, 2024	EX-3.1	Certificate of Fourth Amendment to the Third Amended and Restated Certificate of Incorporation. Exhibit 3.1 CERTIFICATE OF FOURTH AMENDMENT OF THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ENSYSCE BIOSCIENCES, INC. Ensysce Biosciences, Inc., a corporation organized and existing under the General Corporation Law (the “DGCL”) of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: FIRST. The name of the corporation is Ensysce Biosciences, Inc. The Corporation was in
December 3, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 (November 27, 2024) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of inc
November 21, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 (November 21, 2024) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of in
November 19, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
November 14, 2024	SC 13G	ENSC / Ensysce Biosciences, Inc. / Anson Funds Management LP - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No.
November 14, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 d901189dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value, of Ensysce Biosciences, Inc., a Delaware corp
November 12, 2024	EX-99.1	Ensysce Biosciences Reports Third Quarter 2024 Financial Results Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPAR Submitted Pivotal PF614 Phase 3 Protocol to the FDA for Review Exhibit 99.1 Ensysce Biosciences Reports Third Quarter 2024 Financial Results Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPAR Submitted Pivotal PF614 Phase 3 Protocol to the FDA for Review SAN DIEGO, CA / November 12, 2024 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company
November 12, 2024	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 (November 12, 2024) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of in
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38306 Ensysce Biosciences, Inc.
November 6, 2024	SC 13G	ENSC / Ensysce Biosciences, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ensysce Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 293602405 (CUSIP Number) October 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
November 6, 2024	EX-1	Joint Filing Agreement EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 6, 2024 is by and among RA Capital Management, L.
October 29, 2024	EX-99.1	AGREEMENT EX-99.1 2 d136995dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: October 29, 20
October 29, 2024	SC 13G	ENSC / Ensysce Biosciences, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ensysce Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 293602405 (CUSIP Number) October 22, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig
October 18, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
October 18, 2024	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 (October 17, 2024) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of inco
October 18, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
October 18, 2024	EX-3.2B	Amendment, effective November 1, 2024, to Amended and Restated Bylaws of Ensysce Biosciences, Inc. Exhibit 3.2(b) AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF ENSYSCE BIOSCIENCES, INC. (as amended November 1, 2024) Section 1.5 is deleted in its entirety and replaced with the following: Section 1.5. Quorum. At any meeting of the stockholders, the holders of shares of capital stock of the Corporation entitled to cast 1/3rd of the total votes entitled to be cast by the holders of all outstandin
October 15, 2024	CORRESP	Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 October 15, 2024 Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 October 15, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Alan Campbell, Esq. Re: Ensysce Biosciences, Inc. Registration Statement on Form S-3 SEC File No. 333-282563 Filed October 9, 2024 Ladies and
October 10, 2024	DEL AM	DEL AM DEL AM October 10, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 RE: Ensysce Biosciences, Inc. Registration Statement on Form S-3 File No. 333-282563 To Whom It May Concern: Reference is made to the Registration Statement on Form S-3 (File No. 333-282563) filed by Ensysce Biosciences, Inc. (the “Company”) with the Sec
October 9, 2024	POS AM	As filed with the Securities and Exchange Commission on October 9, 2024 As filed with the Securities and Exchange Commission on October 9, 2024 Registration No.
October 9, 2024	S-3	As filed with the Securities and Exchange Commission on October 9, 2024 As filed with the Securities and Exchange Commission on October 9, 2024 Registration No.
October 9, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ensysce Biosciences, Inc.
October 7, 2024	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
August 30, 2024	EX-4.3	Form of Private Placement Agent Warrant Exhibit 4.3 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC
August 30, 2024	EX-99.1	Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants Exhibit 99.1 Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants SAN DIEGO, CA / ACCESSWIRE / August 29, 2024 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, toda
August 30, 2024	EX-4.2	Form of Series A-3/A-4 common stock purchase warrant issued August 29, 2024 (incorporated by reference to Exhibit 4.2 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on August 30, 2024). Exhibit 4.2 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC
August 30, 2024	EX-10.2	Inducement Letter Agreement, dated August 28, 2024 (incorporated by reference to Exhibit 10.2 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on August 30, 2024). Exhibit 10.2 ENSYSCE BIOSCIENCES, INC. August 28, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Ensysce Biosciences, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.0001 per s
August 30, 2024	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 28, 2024, between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi
August 30, 2024	EX-4.1	Form of Pre-funded Warrant Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: [] Initial Exercise Date: , 2024 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date
August 30, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 (August 28, 2024) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 (August 28, 2024) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorp
August 29, 2024	424B5	ENSYSCE BIOSCIENCES, INC. 2,490,798 Shares of Common Stock 1,062,396 Pre-funded Warrants to Purchase up to 1,062,396 Shares of Common Stock Up to 1,062,396 Shares of Common Stock Underlying the Pre-Funded Warrants Filed Pursuant to Rule 424(b)(5) Registration No. 333-269157 PROSPECTUS SUPPLEMENT (To the Prospectus dated January 6, 2023) ENSYSCE BIOSCIENCES, INC. 2,490,798 Shares of Common Stock 1,062,396 Pre-funded Warrants to Purchase up to 1,062,396 Shares of Common Stock Up to 1,062,396 Shares of Common Stock Underlying the Pre-Funded Warrants Pursuant to this prospectus supplement and the accompanying p
August 29, 2024	424B5	ENSYSCE BIOSCIENCES, INC. 2,490,798 Shares of Common Stock 1,062,396 Pre-funded Warrants to Purchase up to 1,062,396 Shares of Common Stock Up to 1,062,396 Shares of Common Stock Underlying the Pre-Funded Warrants Filed Pursuant to Rule 424(b)(5) Registration No. 333-269157 PROSPECTUS SUPPLEMENT (To the Prospectus dated January 6, 2023) ENSYSCE BIOSCIENCES, INC. 2,490,798 Shares of Common Stock 1,062,396 Pre-funded Warrants to Purchase up to 1,062,396 Shares of Common Stock Up to 1,062,396 Shares of Common Stock Underlying the Pre-Funded Warrants Pursuant to this prospectus supplement and the accompanying p
August 23, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2024 (August 20, 2024) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorp
August 14, 2024	EX-99.1	Ensysce Biosciences Reports Second Quarter 2024 Financial Results PF614-MPAR Progressing to Phase 1b Study to Verify Both Overdose Protection and Effective Delivery of Oxycodone Opioid Use Disorder Program Advances with Selection of PF9001 as Lead Dr Exhibit 99.1 Ensysce Biosciences Reports Second Quarter 2024 Financial Results PF614-MPAR Progressing to Phase 1b Study to Verify Both Overdose Protection and Effective Delivery of Oxycodone Opioid Use Disorder Program Advances with Selection of PF9001 as Lead Drug Candidate PF614 Phase 3 Protocol Being Finalized for Submission to FDA SAN DIEGO, CA / August 14, 2024 / Ensysce Biosciences, Inc. (NA
August 14, 2024	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 (August 14, 2024) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorp
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38306 Ensysce Biosciences, Inc.
May 28, 2024	EX-99.1	Ensysce Biosciences Regains Compliance with Nasdaq Exhibit 99.1 Ensysce Biosciences Regains Compliance with Nasdaq SAN DIEGO, CA / May 28, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or the “Company”), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that it has received notice on May 24, 2024 from The Nasdaq Stoc
May 28, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 (May 28, 2024) Ensys UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 (May 28, 2024) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorporatio
May 13, 2024	EX-99.1	Ensysce Biosciences Reports First Quarter 2024 Financial Results PF614’s Phase 3 Clinical Plans Affirm the Path to Regulatory Approval FDA Breakthrough Therapy Designation of PF614-MPAR Expedites Clinical Program Exhibit 99.1 Ensysce Biosciences Reports First Quarter 2024 Financial Results PF614’s Phase 3 Clinical Plans Affirm the Path to Regulatory Approval FDA Breakthrough Therapy Designation of PF614-MPAR Expedites Clinical Program SAN DIEGO, CA / May 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or the “Company”), a clinical stage pharmaceutical company developing innovative solutions f
May 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38306 Ensysce Biosciences, Inc.
May 13, 2024	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 (May 13, 2024) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorporatio
May 9, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 (May 9, 2024) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorporation
April 19, 2024	POS AM	As filed with the Securities and Exchange Commission on April 19, 2024 As filed with the Securities and Exchange Commission on April 19, 2024 Registration No.
April 3, 2024	CORRESP	Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 April 3, 2024 Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 April 3, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Jessica Dickerson, Esq. Re: Ensysce Biosciences, Inc. Registration Statement on Form S-1 SEC File No. 333-276537 Filed January 17, 2024 Pre-Effec
March 29, 2024	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 (March 27, 2024) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorpor
March 26, 2024	S-1/A	As filed with the Securities and Exchange Commission on March 26, 2024 As filed with the Securities and Exchange Commission on March 26, 2024 Registration No.
March 26, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Ensysce Biosciences, Inc.
March 15, 2024	EX-97.1	Policy relating to recovery of erroneously awarded compensation Exhibit 97 ENSYSCE BIOSCIENCES, INC. CLAWBACK POLICY The Board of Directors (the “Board”) of Ensysce Biosciences, Inc., a Delaware corporation (the “Company”) has adopted the following Clawback Policy (this “Policy”) on November 16, 2023, effective as of October 2, 2023 (the “Effective Date”). 1. Purpose. The purpose of this Policy is to provide for the recoupment of certain incentive compensation
March 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2024 (March 15, 2024) E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2024 (March 15, 2024) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorpor
March 15, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38306 ENSYSCE BIOSCIENCES, INC.
March 15, 2024	EX-99.1	Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results ~ Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical Plans ~ Exhibit 99.1 Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results ~ Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical Plans ~ SAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ:ENSC), a clinical-stage company applying
February 15, 2024	424B3	The date of this prospectus supplement is February 14, 2024. ADDITIONAL RISK FACTOR Filed Pursuant to Rule 424(b)(3) Registration No. 333-275456 To the prospectus dated November 17, 2023 PROSPECTUS SUPPLEMENT NO. 1 This prospectus supplement amends and supplements the prospectus dated November 17, 2023, as supplemented or amended from time to time (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (No. 333-275456). This prospectus supplement is being
February 14, 2024	424B3	The date of this prospectus supplement is February 14, 2024. AMENDMENT TO COMMON WARRANTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-271480 To the prospectus dated May 10, 2023 PROSPECTUS SUPPLEMENT NO. 1 This prospectus supplement amends and supplements the prospectus dated May 10, 2023, (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (No. 333-271480). This prospectus supplement is being filed to update and supplement the information in the
February 14, 2024	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2024 (February 12, 2024) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of in
February 14, 2024	SC 13G/A	ENSC / Ensysce Biosciences, Inc. / Lincoln Park Capital Fund, LLC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tm246286d4sc13ga.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ENSYSCE BIOSCIENCES, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 293602207 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this S
February 14, 2024	EX-4.1	Form of Series A/B common stock purchase warrant issued February 14, 2024 (incorporated by reference to Exhibit 4.1 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on February 14, 2024). Exhibit 4.1 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC
February 14, 2024	EX-10.1	Form of Inducement Letter Agreement, dated as of February 12, 2024 (incorporated by reference to Exhibit 10.1 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on February 14, 2024). Exhibit 10.1 ENSYSCE BIOSCIENCES, INC. February 12, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Ensysce Biosciences, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.0001 per
February 14, 2024	EX-10.2	Form of Waiver, dated February 12, 2024, under the Securities Purchase Agreement dated October 23, 2023 ((incorporated by reference to Exhibit 10.2 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on February 14, 2024) Exhibit 10.2 WAIVER UNDER THE SECURITIES PURCHASE AGREEMENT DATED OCTOBER 23, 2023 This Waiver under the Securities Purchase Agreement dated October 23, 2023 (this “Waiver”) is entered into effective as of this 12th day of February 2024 (the “Effective Date”) by and among Ensysce Biosciences, Inc., a Delaware corporation (the “Company”) and each purchaser under the Securities Purchase Agreement, a
February 14, 2024	EX-99.1	Joint Filing Agreement EX-99.1 2 tm246286d4ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the comple
February 14, 2024	EX-4.2	Form of placement agent warrant issued February 14, 2024 (incorporated by reference to Exhibit 4.2 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on February 14, 2024). Exhibit 4.2 NEITHER THE OFFER AND SALE OF THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXC
February 14, 2024	EX-99.1	Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds Exhibit 99.1 Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds SAN DIEGO, CA / ACCESSWIRE / February 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) (the “Company”), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the entry into definitive agreements for t
January 17, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Ensysce Biosciences, Inc.
January 17, 2024	S-1	As filed with the Securities and Exchange Commission on January 16, 2024 As filed with the Securities and Exchange Commission on January 16, 2024 Registration No.
December 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 (December 29, 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 (December 29, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of in
December 19, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of
December 19, 2023	EX-99	Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023 Exhibit 99 Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023 SAN DIEGO, CA, December 19, 2023 — Ensysce Biosciences, Inc.
December 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 (December 19, 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 (December 19, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of in
November 30, 2023	RW	Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 November 30, 2023 Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 November 30, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Joseph McCann, Esq. Re: Ensysce Biosciences, Inc. - Request for Withdrawal – Form RW Relating to the Registration Statement on Form S-3 SEC F
November 29, 2023	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2023 (November 28, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of in
November 29, 2023	EX-99.1	Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing ~ Additional Funding from Investors Validates Company’s Mission ~ Exhibit 99.1 Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing ~ Additional Funding from Investors Validates Company’s Mission ~ SAN DIEGO, CA, November 28, 2023 — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, announced today that it has complet
November 29, 2023	EX-4.6B	Form of First Amendment to the Senior Secured Convertible Note) Exhibit 4.6(b) FIRST AMENDMENT TO SENIOR SECURED CONVERTIBLE NOTE This First Amendment to Senior Secured Convertible Note (this “Amendment”) dated as of November 28, 2023 (the “Effective Date”) is entered into by and between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and (the “Purchaser”). RECITALS A. The Purchaser and the Company entered into that certain Securities Purcha
November 20, 2023	CORRESP	Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 November 20, 2023 Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 November 20, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Jason Drory, Esq. Re: Ensysce Biosciences, Inc. Registration Statement on Form S-1 SEC File No. 333-275456 Filed November 9, 2023 Pre-Effecti
November 17, 2023	S-1/A	As filed with the Securities and Exchange Commission on November 17, 2023 As filed with the Securities and Exchange Commission on November 17, 2023 Registration No.
November 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 (November 13, 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 (November 13, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of in
November 13, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
November 13, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
November 9, 2023	S-1	As filed with the Securities and Exchange Commission on November 9, 2023 As filed with the Securities and Exchange Commission on November 9, 2023 Registration No.
November 9, 2023	EX-4.16	Form of common warrant issued in October 2023 and November 2023 (incorporated by reference to Exhibit 4.16 filed with the registrant’s Registration Statement on Form S-1 (File No. 333-275456) on November 9, 2023). Exhibit 4.16 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
November 9, 2023	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 (November 9, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of inco
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38306 Ensysce Biosciences, Inc.
November 9, 2023	EX-3.2B	Amendment, dated October 5, 2023, to Amended and Restated Bylaws of Ensysce Biosciences, Inc. (incorporated by reference to Exhibit 3.2(b) filed with the registrant’s Registration Statement on Form S-1 (File No. 333-275456) on November 9, 2023). Exhibit 3.2(b) AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF ENSYSCE BIOSCIENCES, INC. (as amended October 5, 2023) Section 1.5 is deleted in its entirety and replaced with the following: Section 1.5. Quorum. At any meeting of the stockholders, the holders of shares of capital stock of the Corporation entitled to cast 1/3rd of the total votes entitled to be cast by the holders of all outstanding
November 9, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Ensysce Biosciences, Inc.
November 9, 2023	EX-99.1	Ensysce Biosciences Reports Third Quarter 2023 Financial Results ~ PF614-201 Clinical Study Results Expected by End of Year ~ Exhibit 99.1 Ensysce Biosciences Reports Third Quarter 2023 Financial Results ~ PF614-201 Clinical Study Results Expected by End of Year ~ SAN DIEGO, CA, November 9, 2023 — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the third quarter of 20
November 9, 2023	EX-10.9C	Form of Restricted Stock Unit Agreement under the Amended and Restated 2021 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.9(c) filed with the registrant’s Registration Statement on Form S-1 (File No. 333-275456) on November 9, 2023). Exhibit 10.9(c) ENSYSCE BIOSCIENCES, INC. AMENDED AND RESTATED 2021 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE AND AWARD AGREEMENT Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), pursuant to its Amended and Restated 2021 Omnibus Incentive Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) the number of restricted stock units set forth
October 30, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
October 24, 2023	EX-10.4	Form of Security Agreement (incorporated by reference to Exhibit 10.4 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on October 24, 2023). Exhibit 10.4 SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of October [*], 2023 (this “Agreement”), is among Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), all of the Subsidiaries of the Company (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”), the holders of the Company’s Senior Secured Convertible Notes due six (6) months following the
October 24, 2023	EX-4.7	Form of Common Stock Purchase Warrant to be issued by the Company pursuant to and in accordance with the Securities Purchase Agreement Exhibit 4.7 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 24, 2023	EX-4.6	Form of October 2023 Secured Convertible Promissory Note (incorporated by reference to Exhibit 4.6 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on October 24, 2023). Exhibit 4.6 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
October 24, 2023	EX-99.1	Ensysce Biosciences Secures $1.7 Million Convertible Note Financing ~ Additional Funding from Investor Cohort Validates Company’s Mission ~ Exhibit 99.1 Ensysce Biosciences Secures $1.7 Million Convertible Note Financing ~ Additional Funding from Investor Cohort Validates Company’s Mission ~ SAN DIEGO, CA, October 24, 2023 — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, announced today that it has entered into a sec
October 24, 2023	EX-10.5	Form of Patent Security Agreement (incorporated by reference to Exhibit 10.5 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on October 24, 2023). Exhibit 10.5 PATENT SECURITY AGREEMENT This PATENT SECURITY AGREEMENT (this “Patent Security Agreement”) is entered into as of October [*], 2023 by and among, Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), all of the Subsidiaries of the Company (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”), the holders of the Company’s Senior Secured Convert
October 24, 2023	EX-10.1	October 2023 Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on October 24, 2023). Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 23, 2023, between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condi
October 24, 2023	EX-10.3	Form of Subsidiary Guaranty (incorporated by reference to Exhibit 10.3 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on October 24, 2023). Exhibit 10.3 SUBSIDIARY GUARANTEE SUBSIDIARY GUARANTEE, dated as of October [*], 2023 (this “Guarantee”), made by each of the signatories hereto (together with any other entity that may become a party hereto as provided herein, the “Guarantors”), in favor of 3i, LP in its capacity as collateral agent (in such capacity, the “Collateral Agent” as hereinafter further defined) for the purchasers signa
October 24, 2023	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 (October 23, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of inco
October 24, 2023	EX-10.2	Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on October 24, 2023). Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of October [*], 2023 between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Pur
October 20, 2023	EX-FILING FEES	Filing fee table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ensysce Biosciences, Inc.
October 20, 2023	S-8	As filed with the Securities and Exchange Commission on October 19, 2023 As filed with the Securities and Exchange Commission on October 19, 2023 Registration No.
August 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 (August 24, 2023) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 (August 24, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorp
August 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38306 Ensysce Biosciences, Inc.
August 11, 2023	EX-99.1	Ensysce Biosciences Reports Second Quarter 2023 Financial Results ~ Progression Toward Full Phase 3 Evaluation of PF614 with Recently Announced IRB Approval of Key Study Protocol ~ Exhibit 99.1 Ensysce Biosciences Reports Second Quarter 2023 Financial Results ~ Progression Toward Full Phase 3 Evaluation of PF614 with Recently Announced IRB Approval of Key Study Protocol ~ SAN DIEGO, CA, August 11, 2023 — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today
August 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 (August 11, 2023) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 (August 11, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorp
July 18, 2023	SC 13D/A	US2936024056 / ENSYSCE BIOSCIEN / GOWER BOB G Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Ensysce Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 293602405 (CUSIP Number) Bob G. Gower 101 Westcott, Unit 303 Houston, Texas 77007 (832) 771-7438 (Name, Address and Telephone Number of
July 14, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of
July 14, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of
June 14, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 (June 13, 2023) Ens UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 (June 13, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorporat
June 14, 2023	EX-99.1	Ensysce Biosciences Regains Compliance with Nasdaq Exhibit No. 99.1 Ensysce Biosciences Regains Compliance with Nasdaq SAN DIEGO, CA / ACCESSWIRE / June 13, 2023 / Ensysce Biosciences, Inc. (the “Company”) (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has demonstrated compliance w
June 2, 2023	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2023 (June 2, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorporatio
May 17, 2023	EX-4.13	Form of pre-funded warrant (incorporated by reference to Exhibit 4.13 filed with the registrant’s Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-271480) on May 17, 2023). Exhibit 4.13 EXHIBIT A-1 PREFUNDED COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: Initial Exercise Date: May [],2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
May 17, 2023	AW	Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 May 17, 2023 Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 May 17, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Re: Ensysce Biosciences, Inc. Post-Effective Amendment No. 1 to Registration Statement on Form S-1 Withdrawal Request – Form type “AW” SEC File No. 333-27148
May 17, 2023	EX-4.12	Form of common warrant (incorporated by reference to Exhibit 4.12 filed with the registrant’s Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-271480) on May 17, 2023). Exhibit 4.12 EXHIBIT A SERIES [A-1] [A-2] COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: Initial Exercise Date: May [], 2023 THIS SERIES [A-1] [A-2] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, a
May 17, 2023	EX-4.14	Form of placement agent warrant (incorporated by reference to Exhibit 4.14 filed with the registrant’s Post-Effective Amendment on Form S-1 (File No. 333-271480) on May 17, 2023). Exhibit 4.14 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: 126,061 Initial Exercise Date: May 12, 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, H.C. Wainwright & Co., LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions herei
May 17, 2023	POS EX	As filed with the Securities and Exchange Commission on May 17, 2023 As filed with the Securities and Exchange Commission on May 17, 2023 Registration No.
May 17, 2023	EX-10.16	Form of Securities Purchase Agreement Exhibit 10.16 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 10, 2023, between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition
May 17, 2023	EX-4.15	Form of warrants amended in connection with the execution of a Securities Purchase Agreement on May 10, 2023 (incorporated by reference to Exhibit 4.15 filed with the registrant’s Post-Effective Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333-271480) on May 17, 2023). Exhibit 4.15 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
May 15, 2023	EX-4.2	Form of Pre-funded Warrant Exhibit 4.2 EXHIBIT A-1 PREFUNDED COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: Initial Exercise Date: May [],2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a
May 15, 2023	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 10, 2023, between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions
May 15, 2023	EX-4.1	Form of Common Warrant Exhibit 4.1 EXHIBIT A SERIES [A-1] [A-2] COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: Initial Exercise Date: May [], 2023 THIS SERIES [A-1] [A-2] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at
May 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 (May 10, 2023) Ensys UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 (May 10, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of (Commission
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38306 Ensysce Biosciences, Inc.
May 15, 2023	EX-99.1	Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering Exhibit 99.1 Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering SAN DIEGO, CA / ACCESSWIRE / May 12, 2023 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) (the “Company”), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the closing of the previously announced public offering of an
May 15, 2023	EX-4.4	Form of warrants amended in connection with the execution of the Securities Purchase Agreement dated May 10, 2023 Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
May 15, 2023	EX-4.3	Form of Placement Agent Warrant Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: 126,061 Initial Exercise Date: May 12, 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, H.C. Wainwright & Co., LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions herein
May 12, 2023	EX-4.15	Form of warrants amended in connection with the execution of the Securities Purchase Agreement Exhibit 4.15 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
May 12, 2023	424B3	The date of this prospectus supplement is May 12, 2023. AMENDMENT TO EXISTING WARRANTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-268858 To the prospectus dated December 31, 2022 PROSPECTUS SUPPLEMENT NO. 1 This prospectus supplement amends and supplements the prospectus dated August 30, 2022, as supplemented or amended from time to time (the “Prospectus”), which forms a part of our Registration Statement on Form S-3 (No. 333-268858). This prospectus supplement is being f
May 12, 2023	424B3	The date of this prospectus supplement is May 12, 2023. AMENDMENT TO EXISTING WARRANTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-267001 To the prospectus dated August 30, 2022 PROSPECTUS SUPPLEMENT NO. 1 This prospectus supplement amends and supplements the prospectus dated August 30, 2022, as supplemented or amended from time to time (the “Prospectus”), which forms a part of our Registration Statement on Form S-3 (No. 333-267001). This prospectus supplement is being fil
May 12, 2023	EX-10.16	Form of Securities Purchase Agreement Exhibit 10.16 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 10, 2023, between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condition
May 12, 2023	EX-4.14	Form of placement agent warrant Exhibit 4.14 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: 126,061 Initial Exercise Date: May 12, 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, H.C. Wainwright & Co., LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions herei
May 12, 2023	424B3	ENSYSCE BIOSCIENCES, INC. 349,000 Shares of Common Stock 1,800,876 Series A-1 Warrants to Purchase 1,800,876 Shares of Common Stock 1,800,876 Series A-2 Warrants to Purchase 1,800,876 Shares of Common Stock 1,451,876 Pre-Funded Warrants to Purchase 1 Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-271480 PROSPECTUS ENSYSCE BIOSCIENCES, INC. 349,000 Shares of Common Stock 1,800,876 Series A-1 Warrants to Purchase 1,800,876 Shares of Common Stock 1,800,876 Series A-2 Warrants to Purchase 1,800,876 Shares of Common Stock 1,451,876 Pre-Funded Warrants to Purchase 1,451,876 Shares of Common Stock Placement Agent Warrants to Purchase
May 12, 2023	424B3	The date of this prospectus supplement is May 12, 2023. AMENDMENT TO EXISTING WARRANTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-268038 To the prospectus dated December 7, 2022 PROSPECTUS SUPPLEMENT NO. 1 This prospectus supplement amends and supplements the prospectus dated August 30, 2022, as supplemented or amended from time to time (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (No. 333-268038). This prospectus supplement is being fi
May 12, 2023	EX-4.12	Form of common warrant Exhibit 4.12 EXHIBIT A SERIES [A-1] [A-2] COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: Initial Exercise Date: May [], 2023 THIS SERIES [A-1] [A-2] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, a
May 12, 2023	POS AM	As filed with the Securities and Exchange Commission on May 12, 2023 As filed with the Securities and Exchange Commission on May 12, 2023 Registration No.
May 12, 2023	EX-4.13	Form of pre-funded warrant Exhibit 4.13 EXHIBIT A-1 PREFUNDED COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: Initial Exercise Date: May [],2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
May 9, 2023	CORRESP	Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 May 9, 2023 Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 May 9, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Daniel Crawford, Esq. Re: Ensysce Biosciences, Inc. Registration Statement on Form S-1 SEC File No. 333-271480 Ladies and Gentlemen: Pursuant to Ru
May 9, 2023	CORRESP	430 Park Avenue \| New York, NY 10022 \| 212.356.0500 \| www.hcwco.com Member: FINRA/SIPC May 9, 2023 VIA FACSIMILE AND EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance Washington, DC 20549 Re: Ensysce Bioscience, Inc. Registration Statement on Form S-1 (Registration No. 333-271480) - Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-efforts basis in an offering purs
May 9, 2023	S-1/A	As filed with the Securities and Exchange Commission on May 9, 2023 As filed with the Securities and Exchange Commission on May 9, 2023 Registration No.
May 9, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Ensysce Biosciences, Inc.
May 8, 2023	S-1/A	As filed with the Securities and Exchange Commission on May 8, 2023 As filed with the Securities and Exchange Commission on May 8, 2023 Registration No.
May 8, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Ensysce Biosciences, Inc.
April 28, 2023	S-1	Power of Attorney (included on signature page to this registration statement). As filed with the Securities and Exchange Commission on April 27, 2023 Registration No.
April 28, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Ensysce Biosciences, Inc.
April 10, 2023	EX-16	Letter from Mayer Hoffman McCann P.C. concerning the change in the Company’s certifying accountant, dated April 10, 2023 Exhibit 16 April 10, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Commissioners: We have read Item 4.01 of Ensysce Biosciences Inc.’s Form 8-K dated April 10, 2023, and we agree with the statements set forth in Item 4.01, insofar as they relate to our firm. We have no basis to agree or disagree with other statements made by the registrant contained in Item 4.01.
April 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 (April 10, 2023) E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 (April 10, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorpor
March 31, 2023	8-A12G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A/A (Amendment No. 2) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Ensysce Biosciences, Inc. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A/A (Amendment No. 2) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 82-2755287 (State or other jurisdiction of incorporation or organization) (I.R.S. Emplo
March 31, 2023	EX-99.1	Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results ~ Corporate Update Call to be Held Tuesday, April 11, 2023 ~ Exhibit 99.1 Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results ~ Corporate Update Call to be Held Tuesday, April 11, 2023 ~ SAN DIEGO, CA, March 30, 2023 — Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today reported financial results for the
March 31, 2023	EX-3.3	Certificate of Elimination of Series A Preferred Stock dated March 31, 2023 (incorporated by reference to Exhibit 3.3 to the Company’s Registration Statement on Form 8-A/A (Amendment No. 2), filed on March 31, 2023, File No. 000-56516). Exhibit 3.3 ENSYSCE BIOSCIENCES, INC. CERTIFICATE OF ELIMINATION OF SERIES A PREFERRED STOCK Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware Ensysce Biosciences, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (“DGCL”), DOES HEREBY CERTIFY: FIRST. Pursuant to the authority expr
March 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 (March 30, 2023) E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 (March 30, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorpor
March 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 (March 28, 2023) E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 (March 28, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorpor
March 30, 2023	EX-14	Company’s Code of Business Conduct (incorporated by reference to Exhibit 14 filed with the registrant’s Annual Report on Form 10-K (File No. 001-38306) on March 30, 2023). Exhibit 14 CODE OF BUSINESS CONDUCT AND ETHICS OF ENSYSCE BIOSCIENCES, INC. 1. Introduction The Board of Directors (the “Board”) of Ensysce Biosciences, Inc. (the “Company”) has adopted this code of business conduct and ethics (this “Code”), as amended from time to time by the Board and which is applicable to all of the Company’s directors, officers and employees to: ● promote honest and ethical c
March 30, 2023	EX-3.1	Certificate of Third Amendment to Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on March 30, 2023). Exhibit 3.1 CERTIFICATE OF THIRD AMENDMENT OF THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ENSYSCE BIOSCIENCES, INC. Ensysce Biosciences, Inc., a corporation organized and existing under the General Corporation Law (the “DGCL”) of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: FIRST. The name of the corporation is Ensysce Biosciences, Inc. The Corporation was incorpo
March 30, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38306 ENSYSCE BIOSCIENCES, INC.
March 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 (March 23, 2023) E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 (March 23, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of incorpor
February 24, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
February 16, 2023	S-3/A	As filed with the Securities and Exchange Commission on February 15, 2023 As filed with the Securities and Exchange Commission on February 15, 2023 Registration No.
February 14, 2023	SC 13G/A	ENSC / Ensysce Biosciences, Inc. / HG Vora Capital Management, LLC - AMENDMENT NO. 3 Passive Investment SC 13G/A 1 ensc213230sc13ga3.htm AMENDMENT NO. 3 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Ensyce Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 293602108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Chec
February 14, 2023	SC 13G/A	US2936022076 / ENSYSCE BIOSCIENCES INC / CVI Investments, Inc. - SC 13G/A Passive Investment SC 13G/A 1 tm235037d17sc13ga.htm SC 13G/A CUSIP No: 293602207 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Ensysce Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title
February 13, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)
February 7, 2023	EX-4.2	Form of warrant issued to a placement agent or its designees in connection with a private placement conducted concurrently with a public offering (incorporated by reference to Exhibit 4.2 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on February 7, 2023). EX-4.2 4 ex4-2.htm Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO A
February 7, 2023	EX-99.1	Joint Filing Agreement EXHIBIT 1 Joint Filing Agreement The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1).
February 7, 2023	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 2, 2023, between Ensysce Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condit
February 7, 2023	EX-3.1	Certificate of Amendment to Certificate of Designation of Series A Preferred Stock EX-3.1 2 ex3-1.htm Exhibit 3.1 EnSYSCE BIOSCIENCES, INC. Certificate of Amendment to Certificate of designation of series A preferred stock Ensysce Biosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (“DGCL”), DOES HEREBY CERTIFY: FIRST: On January 26, 2023, the Board of Directors of the Corporation
February 7, 2023	EX-99.2	Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.2 Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules SAN DIEGO, CA / ACCESSWIRE / February 7, 2023 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) (the “Company”), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that
February 7, 2023	EX-99.1	Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering Exhibit 99.1 Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering FEBRUARY 03, 2023 8:00AM EST SAN DIEGO, CA / ACCESSWIRE / February 3, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the “Company”), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has entered into a def
February 7, 2023	SC 13G	US2936022076 / ENSYSCE BIOSCIENCES INC / Lincoln Park Capital Fund, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ENSYSCE BIOSCIENCES, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 293602207 (CUSIP Number) February 2, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th
February 7, 2023	8-A12G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Ensysce Biosciences, Inc. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 82-2755287 (State or other jurisdiction of incorporation or organization) (I.R.S. Emplo
February 7, 2023	EX-3.2	Certificate of Amendment to Certificate of Designation of the Series A Preferred Stock of Ensysce Biosciences, Inc., dated February 7, 2023 (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form 8-A/A (Amendment No. 1), filed on February 7, 2023, File No. 000-56516) Exhibit 3.2 eNSYSCE BIOSCIENCES, INC. Certificate of Amendment to Certificate of designation of series A preferred stock Ensysce Biosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (“DGCL”), DOES HEREBY CERTIFY: FIRST: On January 26, 2023, the Board of Directors of the Corporation duly approved reso
February 7, 2023	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2023 (February 2, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of inco
February 7, 2023	EX-4.1	Form of warrant issued in connection with a private placement conducted concurrently with a public offering (incorporated by reference to Exhibit 4.1 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on February 7, 2023). Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
February 6, 2023	424B5	ENSYSCE BIOSCIENCES, INC. 3,571,431 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-269157 PROSPECTUS SUPPLEMENT (To the Prospectus dated January 6, 2023) ENSYSCE BIOSCIENCES, INC. 3,571,431 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 3,571,431 shares of our common stock, $0.0001 par value per share, to certain institutional investors at an offering price of $0
February 1, 2023	EX-3.1	Certificate of Designation of the Series A Preferred Stock of Ensysce Biosciences, Inc., dated February 1, 2023 (incorporated by reference to Exhibit 3.1 to the registrant’s Registration Statement on Form 8-A, filed on February 1, 2023, File No. 000-56516) Exhibit 3.1 ENSYSCE BIOSCIENCES, INC. CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Ensysce Biosciences, Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors of the Corporation (the “Board of
February 1, 2023	EX-99	Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of its Common Stock Exhibit 99 Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of its Common Stock SAN DIEGO, CA / ACCESSWIRE / February 1, 2023 / Ensysce Biosciences, Inc.
February 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 (January 31, 202 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 (January 31, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of inco
February 1, 2023	8-A12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Ensysce Biosciences, Inc. (Exact name of regist UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 82-2755287 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification N
January 31, 2023	S-3	As filed with the Securities and Exchange Commission on January 30, 2023 As filed with the Securities and Exchange Commission on January 30, 2023 Registration No.
January 31, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ensysce Biosciences, Inc.
January 31, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 (January 27, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of inco
January 19, 2023	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 (January 18, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of inco
January 19, 2023	EX-99	Investor Presentation dated January 2023 EX-99 2 ex-99.htm Exhibit 99
January 13, 2023	EX-10.6	Letter Agreement, dated January 12, 2023, by and among the Company and the parties signatory thereto (incorporated by reference to Exhibit 10.6 filed with the registrant’s Current Report on Form 8-K (File No. 001-38306) on January 13, 2023). EX-10.6 2 ex10-6.htm Exhibit 10.6 January 12, 2023 3i, LP 140 Broadway FL 38 New York, NY 10005 Anson Investments Master Fund LP c/o Anson Advisors Inc. 155 University Ave., Suite 207 Toronto, ON Canada M5H3B7 Anson East Master Fund LP c/o Anson Advisors Inc. 155 University Ave., Suite 207 Toronto, ON Canada M5H3B7 Re: Modification of the Senior Secured Convertible Notes under the 2022 Purchase Ag
January 13, 2023	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2023 (January 12, 2023) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of inco
January 13, 2023	CORRESP	Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 January 13, 2023 Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 January 13, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Tyler Howes, Esq. Re: Ensysce Biosciences, Inc. Registration Statement on Form S-3 SEC File No. 333-269157 Ladies and Gentlemen: Pursuant to R
January 9, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ensysce Biosciences, Inc.
January 9, 2023	S-3	As filed with the Securities and Exchange Commission on January 6, 2023 As filed with the Securities and Exchange Commission on January 6, 2023 Registration No.
January 9, 2023	EX-4.3	Form of Indenture. (filed herewith) EX-4.3 2 ex4-3.htm Exhibit 4.3 ENSYSCE BIOSCIENCES, INC. and , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS Page Article 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS. 1 1.2 OTHER DEFINITIONS. 4 1.3 INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT. 4 1.4 RULES OF CONSTRUCTION. 5 Article 2 THE SECURITIES 5 2.1 ISSUABLE IN SERIES. 5 2.2 ESTABLISHMENT OF TERMS OF SERIES OF S
January 3, 2023	424B4	ENSYSCE BIOSCIENCES, INC. Up to 5,000,000 Shares of Common Stock and Shares of Common Stock Underlying Notes Up to 522,094 Shares of Common Stock Underlying Warrants Filed Pursuant to Rule 424(b)(4) Registration No. 333-268858 PROSPECTUS ENSYSCE BIOSCIENCES, INC. Up to 5,000,000 Shares of Common Stock and Shares of Common Stock Underlying Notes Up to 522,094 Shares of Common Stock Underlying Warrants This prospectus relates to the issuance by us and the resale by the selling security holders named in this prospectus (the ?Selling Securityholders?) of up to an
December 27, 2022	CORRESP	Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 December 27, 2022 CORRESP 1 filename1.htm Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 December 27, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Cynthia Polynice, Esq. Re: Ensysce Biosciences, Inc. Registration Statement on Form S-3 SEC File No. 333-268858 Ladie
December 19, 2022	S-3	As filed with the Securities and Exchange Commission on December 16, 2022 As filed with the Securities and Exchange Commission on December 16, 2022 Registration No.
December 19, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ensysce Biosciences, Inc.
December 16, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2022 (December 14, 2022) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of in
December 16, 2022	SC 13G	ENSC / Ensysce Biosciences, Inc. / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 293602207 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Ensysce Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 293602207 (CUSIP Nu
December 9, 2022	424B4	ENSYSCE BIOSCIENCES, INC. 2,280,000 Shares of Common Stock Pre-Funded Warrants to Purchase 620,000 Shares of Common Stock Warrants to Purchase 5,800,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-268038 PROSPECTUS ENSYSCE BIOSCIENCES, INC. 2,280,000 Shares of Common Stock Pre-Funded Warrants to Purchase 620,000 Shares of Common Stock Warrants to Purchase 5,800,000 Shares of Common Stock We are offering 2,280,000 shares of our common stock and warrants to purchase 5,800,000 shares of common stock, at a combined public offering price of $
December 8, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 (December 7, 202 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 (December 7, 2022) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of inco
December 8, 2022	EX-4.11	Form of pre-funded warrant delivered by Ensysce Biosciences, Inc. in December 2022 in connection with an underwritten offering (incorporated by reference to Exhibit 4.11 filed with the registrant’s Post-Effective Amendment No. 1 to the registrant’s Registration Statement on Form S-1 (File No. 333-268038) filed December 8, 2022). Exhibit 4.11 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: Issue Date: [●], 2022 Initial Exercise Date: [●], 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any t
December 8, 2022	EX-4.10	Form of warrant delivered by Ensysce Biosciences, Inc. in December 2022 in connection with an underwritten offering (incorporated by reference to Exhibit 4.10 filed with the registrant’s Post-Effective Amendment No. 1 to the registrant’s Registration Statement on Form S-1 (File No. 333-268038) filed December 8, 2022). Exhibit 4.10 COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: Issue Date: [●], 2022 Initial Exercise Date: [●], 2022 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [●], 20
December 8, 2022	POS EX	Form of warrant delivered by Ensysce Biosciences, Inc. in December 2022 in connection with an underwritten offering (incorporated by reference to Exhibit 4.10 filed with the registrant’s Post-Effective Amendment No. 1 to the registrant’s Registration Statement on Form S-1 filed December 8, 2022) As filed with the Securities and Exchange Commission on December 8, 2022 Registration No.
December 8, 2022	EX-99.1	Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering Exhibit 99.1 Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering SAN DIEGO, CA / ACCESSWIRE / December 7, 2022 / Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC),(OTC PINK: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the pricing of an underwritten
December 8, 2022	EX-1.1	Underwriting Agreement and form of lock-up agreement EX-1.1 2 ex1-1.htm Exhibit 1.1 Execution Version ENSYSCE BIOSCIENCES, INC. 2,280,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 620,000 Shares of Common Stock Warrants to Purchase up to 5,800,000 Shares of Common Stock UNDERWRITING AGREEMENT December 7, 2022 Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Ensy
December 6, 2022	CORRESP	Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 December 6, 2022 U.
December 6, 2022	CORRESP	Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 December 6, 2022 Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 December 6, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Alan Campbell, Esq. Re: Ensysce Biosciences, Inc. Registration Statement on Form S-1, as amended SEC File No. 333-268038 Ladies and Gentlemen:
December 5, 2022	S-1/A	As filed with the Securities and Exchange Commission on December 5, 2022 As filed with the Securities and Exchange Commission on December 5, 2022 Registration No.
December 1, 2022	S-1/A	As filed with the Securities and Exchange Commission on November 30, 2022 As filed with the Securities and Exchange Commission on November 30, 2022 Registration No.
December 1, 2022	EX-4.10	Form of warrant delivered by Ensysce Biosciences, Inc. in December 2022 in connection with an underwritten offering (incorporated by reference to Exhibit 4.10 filed with the registrant’s Post-Effective Amendment No. 1 to the registrant’s Registration Statement on Form S-1 filed December 8, 2022). Exhibit 4.10 COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: Issue Date: [?], 2022 Initial Exercise Date: [?], 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [?], 20
December 1, 2022	EX-1	Underwriting Agreement Exhibit 1 ENSYSCE BIOSCIENCES, INC. [?] Shares of Common Stock Pre-Funded Warrants to Purchase up to [?] Shares of Common Stock Warrants to Purchase up to [?] Shares of Common Stock UNDERWRITING AGREEMENT [?], 2022 Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 Ladies and Gentlemen: Ensysce Biosciences, Inc., a Delaware corporation (the ?Company?),
November 18, 2022	S-1/A	As filed with the Securities and Exchange Commission on November 17, 2022 As filed with the Securities and Exchange Commission on November 17, 2022 Registration No.
November 17, 2022	S-1/A	As filed with the Securities and Exchange Commission on November 16, 2022 As filed with the Securities and Exchange Commission on November 16, 2022 Registration No.
November 17, 2022	EX-4.10	Form of Series A/B warrant in connection with this offering. Exhibit 4.10 [SERIES A]/[SERIES B] COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: Issue Date: [●], 2022 Initial Exercise Date: [●], 2022 THIS [SERIES A]/[SERIES B] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafte
November 17, 2022	EX-10.24	Manufacturing Agreement between Johnson Matthey Pharmaceutical Material, Inc. and the Company dated April 7, 2022 (portions of this exhibit have been omitted). Exhibit 10.24 Certain identified information has been excluded from this Exhibit 10.24 because it is both not material and is the type that the registrant treats as private or confidential. Brackets have been inserted where such information was omitted. March 29, 2022 Lynn Kirkpatrick Chief Executive Office Ensysce Biosciences, Inc. 3210 Merryfield Row San Diego, CA 92121 Dear Lynn, Thank you for
November 17, 2022	EX-4.11	Form of pre-funded warrant delivered by Ensysce Biosciences, Inc. in December 2022 in connection with an underwritten offering (incorporated by reference to Exhibit 4.10 filed with the registrant’s Post-Effective Amendment No. 1 to the registrant’s Registration Statement on Form S-1 filed December 8, 2022). Exhibit 4.11 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ENSYSCE BIOSCIENCES, INC. Warrant Shares: Issue Date: [●], 2022 Initial Exercise Date: [●], 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any t
November 17, 2022	EX-1	Underwriting Agreement Exhibit 1 ENSYSCE BIOSCIENCES, INC. [●] Shares of Common Stock Pre-Funded Warrants to Purchase up to [●] Shares of Common Stock Series A Warrants to Purchase up to [●] Shares of Common Stock Series B Warrants to Purchase up to [●] Shares of Common Stock UNDERWRITING AGREEMENT [●], 2022 Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 Ladies and Gentl
November 16, 2022	CORRESP	Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 November 16, 2022 Ensysce Biosciences, Inc. 7946 Ivanhoe Avenue, Suite 201 La Jolla, California 92037 November 16, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Alan Campbell, Esq. Re: Ensysce Biosciences, Inc. Registration Statement on Form S-1 SEC File No. 333-268038 Filed October 28, 2022 Ladies an
November 14, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 (November 14, 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 (November 14, 2022) Ensysce Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38306 82-2755287 (State or other jurisdiction of in
November 14, 2022	EX-99.1	Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614 ~ Acute pain indication may be appropriate, with potential to significantly shorten development path ~ Exhibit 99.1 Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614 ~ Acute pain indication may be appropriate, with potential to significantly shorten development path ~ San Diego, CA (November 14, 2022) Ensysce Biosciences Inc. (?Ensysce? or the ?Company?) (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improv
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38306 Ensysce Biosciences, Inc.

ENSC / Ensysce Biosciences, Inc. - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)